minimal-residual-disease
(2)
The Urine Test That Reads Cancer's Mail Twelve Years Early
No scope, no needle - just a cup of urine and 60 genes worth of warning. Convergent Genomics is betting that bladder cancer leaves a paper trail years before a doctor can see it.
AmMax Bio., Inc.
AmMax Bio is a clinical-stage biotechnology company in Redwood City, California, developing first-in-class cancer therapeutics built on a CSF1R-targeting antibody platform. Founded in 2020 by pharmaceutical veteran Larry Hsu, PhD, in partnership with Amgen, the company advances a pipeline that spans a monoclonal antibody for tenosynovial giant cell tumor (TGCT), a therapy for colorectal cancer minimal residual disease (in partnership with MD Anderson), and a lead antibody-drug conjugate, AMB-104, for acute myeloid leukemia. AmMax's strategy is to de-risk development by combining clinically validated antibodies with established linker-payload technology.